DENTSPLY SIRONA (NASDAQ:XRAY) Director Michael Barber Purchases 15,175 Shares

DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Director Michael Barber purchased 15,175 shares of the business’s stock in a transaction dated Thursday, June 11th. The shares were acquired at an average cost of $9.88 per share, for a total transaction of $149,929.00. Following the acquisition, the director owned 55,943 shares of the company’s stock, valued at approximately $552,716.84. The trade was a 37.22% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website.

DENTSPLY SIRONA Stock Performance

Shares of XRAY traded up $0.05 during mid-day trading on Monday, reaching $10.14. 2,935,013 shares of the company’s stock traded hands, compared to its average volume of 4,807,656. The business’s 50-day moving average price is $10.98 and its 200-day moving average price is $11.71. The stock has a market capitalization of $2.03 billion, a P/E ratio of -3.22, a price-to-earnings-growth ratio of 1.20 and a beta of 0.89. The company has a debt-to-equity ratio of 1.52, a quick ratio of 0.98 and a current ratio of 1.53. DENTSPLY SIRONA Inc. has a 12 month low of $9.40 and a 12 month high of $17.09.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.27 EPS for the quarter, missing analysts’ consensus estimates of $0.28 by ($0.01). DENTSPLY SIRONA had a negative net margin of 17.06% and a positive return on equity of 18.83%. The company had revenue of $880.00 million for the quarter, compared to analyst estimates of $841.80 million. During the same quarter in the prior year, the business earned $0.43 EPS. DENTSPLY SIRONA’s revenue was up .1% compared to the same quarter last year. DENTSPLY SIRONA has set its FY 2026 guidance at 1.400-1.500 EPS. Equities analysts predict that DENTSPLY SIRONA Inc. will post 1.42 earnings per share for the current year.

Hedge Funds Weigh In On DENTSPLY SIRONA

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in DENTSPLY SIRONA by 4.1% during the 3rd quarter. Vanguard Group Inc. now owns 22,006,576 shares of the medical instruments supplier’s stock worth $279,263,000 after purchasing an additional 869,566 shares in the last quarter. First Eagle Investment Management LLC grew its position in DENTSPLY SIRONA by 3.2% during the 4th quarter. First Eagle Investment Management LLC now owns 14,640,555 shares of the medical instruments supplier’s stock worth $167,342,000 after purchasing an additional 458,744 shares in the last quarter. AQR Capital Management LLC grew its position in DENTSPLY SIRONA by 109.8% during the 2nd quarter. AQR Capital Management LLC now owns 13,316,771 shares of the medical instruments supplier’s stock worth $211,470,000 after purchasing an additional 6,970,086 shares in the last quarter. Lazard Asset Management LLC grew its position in DENTSPLY SIRONA by 0.9% during the 3rd quarter. Lazard Asset Management LLC now owns 10,200,525 shares of the medical instruments supplier’s stock worth $129,445,000 after purchasing an additional 92,868 shares in the last quarter. Finally, Southpoint Capital Advisors LP purchased a new position in DENTSPLY SIRONA during the 1st quarter worth approximately $116,000,000. 95.70% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on XRAY. Robert W. Baird raised their price objective on shares of DENTSPLY SIRONA from $12.00 to $14.00 and gave the company a “neutral” rating in a research note on Friday, February 27th. UBS Group lowered their price objective on shares of DENTSPLY SIRONA from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Thursday, May 7th. Bank of America upgraded shares of DENTSPLY SIRONA from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $13.00 to $17.00 in a research report on Thursday, February 19th. Wells Fargo & Company lifted their price target on shares of DENTSPLY SIRONA from $12.00 to $13.00 and gave the stock an “equal weight” rating in a research report on Friday, February 27th. Finally, Weiss Ratings lowered shares of DENTSPLY SIRONA from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Three equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $13.55.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.